PROSPECTIVE RANDOMIZED TRIAL TO ASSESS THE VALUE OF PREEMPTIVE ORAL THERAPY FOR CMV INFECTION FOLLOWING LIVER TRANSPLANTATION

Authors:
  • DSDaniel Seehofer
    Daniel Seehofer
  • CSChristian A. Schmidt
    Christian A. Schmidt
  • HOHelmut Oettle
    Helmut Oettle
  • AMAndrea R. Muller
    Andrea R. Muller
  • TSThomas Steinmuller
    Thomas Steinmuller
  • USUtz Settmacher
    Utz Settmacher
  • PNPeter Neuhaus
    Peter Neuhaus
Publisher website
Google Scholar
Abstract
With the development of sensitive tests to detect cytomegalovirus (CMV) viremia, preemptive approaches become a reasonable alternative to general CMV prophylaxis. We performed a randomized trial comparing pp65-antigenemia guided preemptive therapy using oral ganciclovir with symptom-triggered intravenous ganciclovir treatment. Eighty-eight of 372 liver transplant recipients developed antigenemia early after orthotopic liver transplantation. Twenty-eight symptomatic patients with antigenemia were excluded from randomization and treated with intravenous ganciclovir. Sixty pp65-antigen–positive asymptomatic patients were randomized to receive either oral ganciclovir 3×1 g/day for 14 days (group 1) or no preemptive treatment (group 2). Patients that developed CMV disease were treated with intravenous ganciclovir 2×5 mg/kg body weight for 14 days. The high-risk (Donor+/Recipient−) patients were equally distributed in the two study groups. Three of 30 (10%) patients on oral ganciclovir developed mild to moderate CMV disease compared with 6/30 (20%) patients in the control group. In the Donor+/Recipient− patients, the incidence of CMV disease was 1/6 and 3/7. All disease episodes resolved after intravenous treatment. The 1- and 3-year patient and organ survival was the same in the study groups and in the patients with or without CMV infection. No deaths related to CMV occurred. The positive predictive value of pp65-antigenemia for the development of CMV disease was very low, and, in 28/88 patients (32%), antigenemia did not precede symptoms. Therefore, pp65-antigenemia is of limited value in deciding on the timing and need for ganciclovir therapy after liver transplantation.

This publication has 31 references indexed in Scilit: